Colorado firm aims to commercialize CU breakthroughs in pain management

Xalud Therapeutics will work with CU doctor's invention
By Staff

The CU Technology Transfer Office recently executed an option agreement with Colorado-based Xalud Therapeutics Inc., giving Xalud the right to commercialize a novel approach for treating neuropathic pain and other diseases of the central nervous system.

The company's lead product candidate, invented by Dr. Linda Watkins of CU-Boulder, is a proprietary, non-narcotic-based therapy that eliminates neuropathic pain in highly predictive, gold-standard rodent models. Xalud also believes its treatment approach might be effective against diseases of the central nervous system.

Neuropathic pain is a chronic, debilitating condition affecting millions of people in the U.S., and is expected to grow into an $8.5 billion market by 2018.